A Single-blind Phase 1 Study Assessing the Safety, Immunogenicity and Low Density Lipoprotein Cholesterol (LDLc)-Lowering Activity of 2 Different Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Targeting AFFITOPE Vaccines in Healthy Subjects

Trial Profile

A Single-blind Phase 1 Study Assessing the Safety, Immunogenicity and Low Density Lipoprotein Cholesterol (LDLc)-Lowering Activity of 2 Different Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Targeting AFFITOPE Vaccines in Healthy Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2016

At a glance

  • Drugs ATH 04 (Primary) ; ATH 06 (Primary) ; Adjuvants
  • Indications Atherosclerosis
  • Focus Adverse reactions
  • Acronyms AFF012
  • Sponsors AFFiRiS
  • Most Recent Events

    • 09 Sep 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Sep 2017.
    • 27 May 2016 Planned End Date changed from 1 Nov 2016 to 1 Dec 2016.
    • 03 Feb 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top